The U.S. Food and Drug Administration (FDA) has released afinal guidanceaddressing their regulatory priorities for drug products labeled as homeopathic. The document follows FDA’s October 2019 withdrawal of Compliance Policy Guide (CPG) 400.400, which had previously described inspectional policies for homeopathic drug products. The final guidance, which includes a list or product categories which FDA states it intends to prioritize for regulatory and enforcement action, is largely unchanged from its most recent draft version. The initial draft guidance had been published in December of 2017.
